ProKidney

ProKidney opened higher and rallied throughout the regular session, closing up 5.56% at $1.995, marking both intraday and closing highs, driven primarily by progress updates on its pivotal Phase 3 clinical trial and better-than-expected Q1 earnings. The company highlighted that results from the Phase 3 PROACT 1 trial for rilparencel are expected in Q2 2027, while Q1 revenue of $226K narrowly beat estimates and EPS of -$0.14 surpassed the analyst consensus of -$0.17, though R&D spending growth widened net loss by 19.74% YoY to $20.037 million. The stock now trades above both its 20-day MA ($1.784) and 60-day MA ($1.835), yet remains 72.02% below its 52-week high of $7.13 and down 10.54% year-to-date, though post-market trading saw the price slip to $1.95, suggesting some short-term profit-taking.